Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2003-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1210/JC.2003-030374PMID 12915681
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eplerenone: a selective aldosterone receptor antagonist (SARA).

  2006cited by this paper
• Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans.

  2002cited by this paper
• Effect of Spironolactone on Impaired Fibrinolysis of Hypertensive Patients

  2002cited by this paper
• ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time

  2002cited by this paper
• Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session.

  2002cited by this paper
• Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

  2002cited by this paper
• Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women with hypertension

  2001cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.

  2000cited by this paper
• Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo.

  2000cited by this paper
• A double-blind, crossover study of the antihypertensive efficacy of angiotensin II-receptor antagonists and their activation of the renin-angiotensin system

  2000cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 Production*

  1999cited by this paper
• Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.

  1999cited by this paper
• Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis.

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.

  1999cited by this paper
• Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.

  1999cited by this paper
• Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.

  1999cited by this paper
• Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.

  1998cited by this paper
• Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels.

  1997cited by this paper
• The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction.

  1997cited by this paper
• Potentiation of angiotensin II action by corticosteroids in vascular tissue.

  1996cited by this paper
• Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension.

  1996cited by this paper
• Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men.

  1995cited by this paper
• Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.

  1995cited by this paper
• Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.

  1995cited by this paper
• Aldosterone escape during ACE inhibitor therapy in chronic heart failure.

  1995cited by this paper
• Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats.

  1994cited by this paper
• Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

  1992cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures.

  1991cited by this paper
• Increase in plasma aldosterone during prolonged captopril treatment.

  1982cited by this paper
• Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects.

  1979cited by this paper
• Inhibition of Renin Secretion by Angiotensin .II.∗

  1965cited by this paper

• The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction

  2025cites this paper
• Orchestra of ligand-activated transcription factors in the molecular symphony of SERPINE 1 / PAI-1 gene regulation.

  2024cites this paper
• COVID-19 associated thyroid dysfunction and other comorbidities and its management using phytochemical-based therapeutics: a natural way

  2023cites this paper
• Does the Serum Concentration of Angiotensin II Type 1 Receptor Have an Effect on the Severity of COVID-19? A Prospective Preliminary Observational Study among Healthcare Professionals

  2022cites this paper
• Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity.

  2021cites this paper
• Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19?

  2020cites this paper
• COVID-19 and the renin-angiotensin system (RAS): A spark that sets the forest alight?

  2020cites this paper
• Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis

  2020cites this paper
• Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise

  2019cites this paper
• PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI - 1) AS A POTENTIAL DIAGNOSTIC AND THERAPEUTIC TARGET

  2018cites this paper
• Association Between Matrix Metalloproteinase-3 Activity and Glomerular Filtration Rate and Albuminuria Status in Patients With Type 2 Diabetes Mellitus.

  2018cites this paper
• Physiology and pathophysiology of the plasminogen system in the kidney

  2017cites this paper
• Inflammatory/Hemostatic Biomarkers and Coronary Artery Calcium Progression in Women at Midlife (from the Study of Women's Health Across the Nation, Heart Study).

  2016cites this paper
• INFLAMMATORY AND HEMOSTATIC BIOMARKERS AND CORONARY ARTERY CALCIFICATION IN WOMEN UNDERGOING THE MENOPAUSAL TRANSITION

  2014cites this paper
• Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity.

  2013cites this paper
• Angiotensin II-aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase.

  2012cites this paper
• Étude de l'implication des cellules musculaires lisses vasculaires dans la distensibilité et le phénotype thrombotique dans des modèles murins

  2012cites this paper
• Association between the rs6950982 polymorphism near the SERPINE1 gene and blood pressure and lipid parameters in a high-cardiovascular-risk population: interaction with Mediterranean diet

  2012cites this paper
• Hypertension, hypercoagulability and the metabolic syndrome: A cluster of risk factors for cardiovascular disease

  2012cites this paper
• Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study

  2011cites this paper
• The role of renin-angiotensin system in prothrombotic state in essential hypertension.

  2010cites this paper
• Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients

  2010cites this paper
• The clinical pharmacology of eplerenone.

  2009cites this paper
• PAI-1 and kidney fibrosis.

  2009cites this paper
• The clinical pharmacology of eplerenone

  2009cites this paper
• Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial †

  2009cites this paper
• Aldosterone and vascular inflammation.

  2008cites this paper
• Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

  2008cites this paper
• Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage.

  2008cites this paper
• Levels of PAI-1 and outcome after electrical cardioversion for atrial fibrillation.

  2008cites this paper
• Modulation of glomerulosclerosis

  2007cites this paper
• Chronic blockade of the angiotensin II receptor has a differential effect on adipose and vascular PAI-1 in OLETF rats.

  2006cites this paper
• Candesartan.

  2006cites this paper
• Progression versus regression of chronic kidney disease.

  2006cites this paper
• The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems.

  2005cites this paper
• Einfluss des AT 1 -Rezeptorantagonismus auf die Hypercholesterinämie-induzierte endotheliale Dysfunktion

  2005cites this paper
• Renal Protective Effects of the Renin-Angiotensin-Aldosterone System Blockade: From Evidence-Based Approach to Perspectives

  2005cites this paper
• Is the Effect of Antihypertensive Drugs on Platelet Aggregability and Fibrinolysis Clinically Relevant?

  2005cites this paper
• Biochemical risk markers: a novel area for better prediction of renal risk?

  2005cites this paper
• Pleiotropic functions of plasminogen activator inhibitor‐1

  2005cites this paper
• Angiotensin in atherosclerosis

  2004cites this paper
• C-reactive protein and albuminuria: independent risk markers of renal and cardiovascular disease

  2004cites this paper